EUCTR2007-001370-88-GB进行中（未招募）不适用
A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer. - SOLE Study of Letrozole Extension
International Breast Cancer Study Group (IBCSG)0 个研究点目标入组 4,800 人开始时间: 2009年11月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 4,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Patients must be postmenopausal definitive confirmation of postmenopausal status is required. 2. Patients must be accessible for follow-up. 3. At diagnosis, patients must have had operable, non-inflammatory breast cancer. 4. Patients must be clinically disease-free at randomization 5. Patients must have had steroid hormone receptor positive tumors (ER and/or PgR), determined by immunohistochemistry, after primary surgery and before commencement of prior endocrine therapy. 6. Following primary surgery, eligible patients must have had evidence of lymph node involvement either in the axillary or internal mammary nodes, but not supraclavicular nodes. 7. There must have been no evidence of recurrent disease or distant metastatic disease at any time prior to randomization. 8. Patients must have had proper local treatment including surgery with or without radiotherapy for primary breast cancer with no known clinical residual loco-regional disease. 9. Patients must have clinically adequate hepatic function. 10. Patients must have completed 4 to 6 years of prior adjuvant endocrine therapy with SERM(s), aromatase inhibitor(s), or a sequential combination of both. When calculating 4-6 years, neoadjuvant endocrine therapy should not be included. 11. Patients must have stopped prior endocrine SERM/AI therapy, and must be randomized within 12 months (1 year) of the last dose of prior endocrine SERM/AI therapy. 12. Patients may have received any type of prior adjuvant therapy, including but not limited to neoadjuvant chemotherapy, neoadjuvant endocrine therapy, adjuvant chemotherapy, trastuzumab, ovarian ablation, GnRH analogues, lapatinib. 13. Patients must have stopped hormone replacement therapy (HRT), bisphosphonates (except for treatment of bone loss), or any investigational agent at randomization. 14. Pathology material from the primary tumor must be available for submission for central review as part of the quality control measures for this protocol. 15. Written Informed Consent (IC) must be signed and dated by the patient and the investigator prior to randomization. 16. Written consent to pathology material submission, indicating the patient has been informed of and agrees to tissue material use, transfer and handling, must be signed and dated by the patient and the investigator prior to randomization.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients who have had bilateral breast cancer. 2. Patients who have had a bone fracture due to osteoporosis at any time during the 4-6 years of prior endocrine SERM/AI therapy. 3. Patients who have had any previous or concomitant malignancy EXCEPT adequately treated: basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, contra- or ipsilateral in situ breast carcinoma. 4. Patients who have had any other non-malignant systemic diseases (cardiovascular, renal, lung, etc.) that would prevent prolonged follow-up. 5. Patients with psychiatric, addictive, or any disorder which compromises compliance with protocol requirements
研究者
相似试验
进行中（未招募）
1 期
A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer - Study of Letrozole Extension (SOLE)Postmenopausal women who are disease-free following 4-6 years of prior adjuvant endocrine therapy with selective estrogen receptor modulator(s) (SERM) and/or aromatase inhibitor(s) (AI) for endocrine-responsive, node-positive operable breast cancer.MedDRA version: 9.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2007-001370-88-GRInternational Breast Cancer Study Group (IBCSG)4,884
进行中（未招募）
1 期
Study of Letrozole Extension (SOLE)EUCTR2007-001370-88-IEInternational Breast Cancer Study Group (IBCSG)4,800
进行中（未招募）
1 期
Study of Letrozole Extension (SOLE)Postmenopausal women who are disease-free following 4-6 years of prior adjuvant endocrine therapy with selective estrogen receptor modulator(s) (SERM) and/or aromatase inhibitor(s) (AI) for endocrine-responsive, node-positive operable breast cancer.MedDRA version: 19.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-001370-88-ATInternational Breast Cancer Study Group (IBCSG)4,884
进行中（未招募）
1 期
A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer - Study of Letrozole Extension (SOLE)EUCTR2007-001370-88-SEInternational Breast Cancer Study Group (IBCSG)4,800
进行中（未招募）
1 期
Study of Letrozole Extension (SOLE)Postmenopausal women who are disease-free following 4-6 years of prior adjuvant endocrine therapy with selective estrogen receptor modulator(s) (SERM) and/or aromatase inhibitor(s) (AI) for endocrine-responsive, node-positive operable breast cancer.MedDRA version: 20.0Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-001370-88-DEInternational Breast Cancer Study Group (IBCSG)4,800